CN103272011B - Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition Download PDFInfo
- Publication number
- CN103272011B CN103272011B CN201310229899.XA CN201310229899A CN103272011B CN 103272011 B CN103272011 B CN 103272011B CN 201310229899 A CN201310229899 A CN 201310229899A CN 103272011 B CN103272011 B CN 103272011B
- Authority
- CN
- China
- Prior art keywords
- group
- kidney
- index
- pharmaceutical composition
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for treating flu. The weight ratio of raw medicine materials including ephedra, asarum and radix aconiti praeparata is (1-3):(2-3):(5-7). The preparation method comprises the steps as follows: the raw medicine materials are mixed and then immersed in distilled water for 30 min; decoction is performed for two times by adding water with an amount of 8 times and 6 times of that of the raw medicine materials respectively, the decoction for the first time lasts for 30 min, and the decoction for the second time lasts for 20 min; filtering liquids are combined; and centrifugation is performed for 10 min at the speed of 3000 r/min, so that a solid dosage form or a liquid dosage form is prepared. The pharmaceutical composition which is prepared through the raw medicine materials with a specific proportion is used for treating external flu of crowds suffering from deficiency of kidney-yang, flu of crowds suffering from hypoimmunity and flu of crowds suffering from underlying diseases and the like. Experiments on animals show that the proportion of treatment effects is obviously larger than the proportion disclosed in the prior art, the death rate is reduced, the death protection rate is raised, the weight, the temperature and all visceral indexes are improved to a great extent, the usage amount of the raw medicine materials is small, the effect is good, the preparation method is simple, and the cost is low.
Description
Technical field
The present invention relates to field of traditional Chinese medicine technology, particularly a kind of pharmaceutical composition for the treatment of influenza, also relates to the preparation method of described pharmaceutical composition.
Background technology
Influenza (Influenza) is called for short influenza, is a kind of acute suction tract disease with hyperinfection caused by influenza virus.It threatens one of maximum infectious disease to human health, has that infectiousness is strong, sickness rate is high, a popular wide and mortality rate high, is that the pandemic infection that the mankind still can not effectively control so far is sick.
Influenza clinical symptoms is heavier, and onset is hurried, and complication rate is high, can cause death, and the dead is mostly many diseases or have the high-risk group of basic chronic patient old and weak and childhood.Mainly comprise: 1. age >65 year; 2. chronic pulmonary or cardiovascular system diseases is had to be grown up and >6 month child (comprising asthma); 3. renal dysfunction; 4. immunological function repression (comprising Drug) person; 5. mid trimester of pregnancy above anemia of pregnant woman etc., there is no specific drug treatment influenza so far.Influenza A H1N1 in 2009, in China, ground adds up report H1N1 influenza severe cases 4328 example, dead 326 examples.In severe cases, the case of 32% has chronic underlying diseases; In death, the case of 47% has chronic underlying diseases.As can be seen here, a high-risk group of the basic chronic patient of weak and sickly, hypoimmunity always all previous influenza!
Doctor trained in Western medicine there is no specific treatment medicine at present, mainly takes anti symptom treatment etc.Current modern medicine for the control of influenza mainly based on the Developing Application of antiviral drugs and specificity vaccine, but take oseltamivir phosphate capsule as problems such as Tamiflu many existence treatments limitation, drug resistance, the untoward reaction of representative, vaccine also just has defense reaction, to the virus morphed without preventive effect for the Virus Type of current popular.Influenza vaccines were once thought a kind of effective preventive measure by modern medicine, but because influenza virus variation is fast, break out rapidly; Relatively lagging behind of influenza vaccines development and application, even if after inoculation, the reasons such as the effective percentage of flu-prevention is low, cause up to now, and for the preventing and controlling influenza of high-risk group, western medicine is particularly preferred measure never.
The control of influenza virus susceptible high-risk group is a modern medicine difficult problem urgently to be resolved hurrily always, and influenza that this crowd suffers from belongs to Kidney Theory in TCM yang deficiency exogenous disease more.The advantage of this disease of Chinese medicine is determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, " the whole synthesis adjustment " of the Chinese medicine compound multicomponent under organic conception instructs, multipath, Mutiple Targets." Ephedra asarum Radix Aconiti Lateralis Preparata soup " is the classic prescriptions of " Treatise on Febrile and Miscellaneous Disease " treating simultaneous occurrence of syndromes in both YANG and YIN channels (i.e. insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor) very little, be made up of Herba Ephedrae, Herba Asari, gun additioner three taste medicine, have effect of dispelling cold by warming the meridian, strengthening vital QI to eliminate pathogenic factors, invigorating YANG and expelling the pathogenic factor in the superficies, clinical prolonged application and modern pharmacological research all prove that it is evident in efficacy.But the proportioning of three taste medicines disclosed in prior art, the present inventor thinks it is not the best proportioning of effect.
Summary of the invention
Not the best problem of effect to solve the proportionings such as the Ephedra asarum Radix Aconiti Lateralis Preparata soup that exists in above prior art, the invention provides a kind of pharmaceutical composition of the treatment influenza containing Herba Ephedrae, Herba Asari, Radix Aconiti Lateralis Preparata of better effects if.
Present invention also offers the preparation method of the pharmaceutical composition of described treatment influenza.
The present invention is achieved by the following measures:
Treat a pharmaceutical composition for influenza, crude drug weight proportion is as follows:
Herba Ephedrae: Herba Asari: Radix Aconiti Lateralis Preparata=1-3:2-3:5-7.
Treat a pharmaceutical composition for influenza, crude drug weight proportion is as follows:
Herba Ephedrae: Herba Asari: Radix Aconiti Lateralis Preparata=2:3:5.
Treat a pharmaceutical composition for influenza, crude drug weight proportion is as follows:
Herba Ephedrae: Herba Asari: Radix Aconiti Lateralis Preparata=3:2:7.
The preparation method of described pharmaceutical composition, after being mixed by crude drug, distilled water immersion 30min, adds 8 times respectively and 6 times of water gagings carry out twice decoction, one decocts 30min, and two decoct 20min, merging filtrate, 3000r/min, centrifugal 10min, make solid dosage forms or liquid dosage form.
Described preparation method, solid dosage forms is tablet, capsule, granule or pill.
Described preparation method, liquid dosage form is oral liquid, mixture, Emulsion, microemulsion or injection.
Beneficial effect of the present invention:
The pharmaceutical composition of the present invention that crude drug adopts specific proportioning obtained; be used for the treatment of kidney yang deficiency syndrome crowd diseases caused by exogenous pathogenic factor; or the influenza of hypoimmunity crowd or suffer from the influenza of the crowds such as underlying disease; shown by results of animal; therapeutic effect is significantly better than proportioning disclosed in prior art; mortality rate reduces; Death prevention rate raises; having body weight, body temperature, each organ index and improve significantly, is the medicine of effective treatment kidney yang deficiency syndrome influenza that a kind of crude drug consumption is few, effective, preparation method is simple, cost is low.
Detailed description of the invention
For a better understanding of the present invention, further illustrate below in conjunction with specific embodiment.
embodiment 1:
Herba Ephedrae 1g, Herba Asari 2g, gun additioner 5g.
embodiment 2:
Herba Ephedrae 2g, Herba Asari 3g, gun additioner 5g.
embodiment 3:
Herba Ephedrae 3g, Herba Asari 2g, gun additioner 7g.
comparative example 1:
Herba Ephedrae 6g, Herba Asari 3g, gun additioner 9g.
comparative example 2:
Herba Ephedrae 6g, Herba Asari 3g, gun additioner 3g.
comparative example 3:
Herba Ephedrae 6g, Herba Asari 6g, gun additioner 6g.
The preparation method of above-mentioned 6 pharmaceutical compositions: by crude drug according to after proportioning mixing, distilled water immersion 30min, add 8 times respectively and 6 times of water gagings carry out twice decoction, one decocts 30min, and two decoct 20min, merging filtrate, 3000r/min, centrifugal 10min, by concentration of liquid medicine to same volume, 4 DEG C of refrigerators are for subsequent use.
effect test
one, the effect comparison test of existing medicine and proportioning raw materials
1, experiment material1.1 laboratory animal
KM mice 20 ± 2g, male, SPF level, is provided (credit number: SCXK (Shandong) 20080002) by the anti-animal experimental center in Shandong, Shandong.Feeding environment: room temperature 22-26 DEG C, relative humidity 40-70%RH.
1.2 experimental apparatus
Electro-heating standing-temperature cultivator, Shanghai Fuma Experiment Equipment Co., Ltd.'s (product type: DPX-9082B-1);
SW-CJ-1C type superclean bench (Purifying Equipment Co., Ltd., Suzhou);
MC-142L type electronic clinical thermometer (Dalian Omron (China) Co., Ltd.);
ZIL-2 type mice autonomic activities instrument (Beijing Medical institute medicine grinds institute);
DT-880B hand-held infrared quick sieving instrument of human body temperature (Shenzhen Hua Shengchang machinery Industrial Co., Ltd.);
1.3 experiment reagent
Mus pneumonopathy strain FM1 influenza virus A type (Influenza Virus A, Flu A) Beijing strains, draws from Chinese CDC virosis institute;
Estradiol benzoate (Ningbo second hormone factory, 120606) injection soybean oil (Zhejiang Tian Yushan medicinal oil company limited, lot number 120502);
Herba Ephedrae, gun additioner, Herba Asari (prepared slices of Chinese crude drugs factory of Jian Lian Chinese medicine company limited of Jinan City, 20110501), standard under the qualification of TCD identification teaching and research room of Shandong Traditional Chinese Medicine University meets Chinese Pharmacopoeia version continuous item in 2010;
SPF Embryo Gallus domesticus is purchased from Domestic Fowls Inst., Shandong Academy of Agricultural Sciences.
, experimental technique
Copying of 2.1 mice with kidney-yang deficiency models
By KM male mice 80, be divided into matched group 10, modeling group 70 at random.Control group mice 20mLKg
-1lumbar injection 0.9% normal saline; Modeling group list of references method also improves modeling dosage, 20mLKg
-1lumbar injection 0.4mgmL
-1estradiol benzoate diluent, every day 1 time, continuous 15d, copies kidney-yang deficiency model, carries out index of correlation detection in modeling 12 ~ 13d, by measuring autonomic activities, anus temperature, toe temperature, swimming time, with this decision model success or not.
2.2 " insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor " Establishment of mouse model
Successful modeling group mice will be copied with body weight and anus temperature for variable, be divided into 5 groups at random, be respectively insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, ribavirin matched group, embodiment 2 medicine group, comparative example 1 medicine group, comparative example 2 medicine group, comparative example 3 medicine group, Influenza B virus allantoic fluid (Hemagglutination titer is 1:320) the collunarium infecting mouse of the high hemagglutinative titer that above-mentioned testing sieve is selected, the normal chick embryo allantoic liquid of 50 μ L of control group mice collunarium inoculation equivalent, 0d is before virus inoculation, 1d inoculates influenza virus, 2 ~ 5d is pharmaceutical intervention treatment, record Mice Body mass change every day (to weigh, survey body temperature), observe the mental status of mice, morbidity and death condition.
2.3 dosage designs
Positive drug group, be all equivalent to people's clinical equivalent dosage by reagent group, infect 2d administration, matched group, model group are with 10mLKg
-1volume gavage distilled water, all the other groups gavage the ribavirin of same volume and the experimental group medicine of different ratio, successive administration 5d, every day gavage 1 time.
2.4 observation index
(1) anus temperature change: the body temperature measuring mice before and after inoculation influenza virus, record variation tendency every day.
(2) changes of body mass: every day Weighing body quality 1 time, continuous 7d.
(3) clinical symptoms: observe the changes such as each group of mice mental status, mobility, diet.
(4) death toll and mortality rate: mortality rate=dead animal number (only)/animal number (only) × 100%, Death prevention rate=[(model group death toll-administration group death toll)/model control group death toll] × 100%.
(5) organ index: after experiment terminates, pluck eyeball and get blood (not adding anticoagulant heparin), 3500r/min is centrifugal, and 10min gets serum ,-70 DEG C of freezen protective, for subsequent use.Get the tissues such as each group of mouse lung, spleen, thymus, take organ weights, calculate organ index.
2.5 statistical analysis
Adopt SPSS11.5 software, data with
± S represents, the comparison of mortality rate adopts x
2statistical procedures is carried out in inspection, and compare between group and adopt one factor analysis of variance (one-way ANOVA) LSD to check, P<0.05 is for there being statistical significance.
experimental result
3.1 impacts on mouse model body weight
Though control group mice body weight has reduction, recover gradually, 5th ~ 6d, body weight rises appreciably; From inoculation influenza virus, though insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Weight is in the trend continuing to reduce until 6d has no recovery, modeling 2d rises and compares with control group mice, has significant difference (P<0.01), this treated animal general performance is low, and mortality rate is high; Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, though ribavirin group Mouse Weight is in the trend reduced, recover gradually, pharmaceutical intervention 3d rises, and has significant difference (P<0.05); Comparative example 2 and comparative example 3 experimental mice body weight change not obvious, all in reduction trend, and have no obvious recovery; Comparative example 1 experimental mice body weight is just in reduction trend, and administration 2d rises in ascendant trend (P<0.05) gradually; Embodiment 2 experimental mice body weight is just in reduction trend, and administration 3d plays the trend in rising gradually, compares, have significance difference (P<0.05) with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group; Wherein increase comparatively obvious with embodiment 2 experimental mice body weight.In table 1.Note: compare with matched group,
* p<0.01; Compare with model group,
# p<0.05.
Table 1 is group Mouse Weight change contrast table respectively
3.2 impacts on mouse model body temperature
1st ~ 6d control group mice anus temperature is apparently higher than other group mices, and difference has statistical significance (P<0.01); 1st ~ 7d insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mice anus temperature is that significance reduces (P<0.01), compares body temperature significance reduce (P<0.05) with other drug treatment group; 3d rises, and test each group of mice anus temperature and go up in various degree, 7d compares with matched group, anus temperature there was no significant difference (P>0.05); 1st ~ 7d compares with matched group anus temperature, and insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group (P<0.01) and embodiment 2 experimental group (P<0.01) have significant difference.In table 2, note: compare with matched group, * P<0.01; Compare with model group, #P<0.05.Table 2 is group mouse temperature change contrast table respectively
3.3 impacts on mouse model mortality rate
Use Influenza B virus infecting mouse, matched group is without death, and insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mortality rate 60%, has higher mortality rate.Ribavirin group mortality rate 27.27%, Death prevention rate 50.00%; Comparative example 3 experimental group mortality rate 36.36%, Death prevention rate 33.33%; Comparative example 2 experimental group mortality rate 18.18%, Death prevention rate 66.67%; Comparative example 1 experimental group mortality rate 9.09%, Death prevention rate 83.33%; Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, experimental group medicine all has the trend reducing insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor mouse death rate in various degree, and wherein embodiment 2 experimental group is without mortality rate.In table 3.
Table 3 on the impact of death toll, mortality rate (
± S, n=X)
3.4 impacts on mouse model Lung Exponent
Compare with control group mice after experiment terminates, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse lung index obviously increases, difference has statistical significance (P<0.01), insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse lung index is apparently higher than other each medication therapy groups, difference has statistical significance (P<0.05), shows obviously to improve through treatment pulmonary infection degree.Wherein to improve effect best for the lungs index of embodiment 2 experimental group.In table 4.
Table 4 and on the impact of lungs index (
± S, n=X)
Note: compare with matched group, * p<0.01; Compare with model group, #p<0.05
3.5 impacts on mouse model organ index
Spleen index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse spleen index reduces significantly, has significant difference (P<0.01); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse spleen index, ribavirin and each experimental mice spleen index obviously raise, and difference has statistical significance (P<0.05), and wherein embodiment 2 experimental group raises the most obvious.
Thymus index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse thymus index obviously reduces, there is significant difference (P<0.01), and ribavirin group and comparative example 2 experimental group, though thymus index comparatively insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse thymus index raises to some extent, but be not yet increased to normal level, significant difference (P<0.05) is still had with control group mice, and other drug experimental group there was no significant difference (P>0.05); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group thymus index, except control group mice, comparative example 1 experimental group and embodiment 2 experimental mice thymus index obviously raise, and have significant difference (P<0.05).
Renal index: compare with control group mice, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Kidney index obviously reduces, there is significant difference (P<0.01), except comparative example 3 experimental group, raise in various degree though all the other each medication therapy groups Mouse Kidney indexes have but still there is significant difference (P<0.01).
Testis index: compare with control group mice, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse testis index obviously reduces, there is significant difference (P<0.01), raise in various degree though each medication therapy groups mouse testis index has, but still there is significant difference (P<0.01); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, though ribavirin group and comparative example 3 experimental mice testis index have certain amplitude to raise, but there was no significant difference (P>0.05), all the other medication therapy groups mouse testis index elevation amplitude are comparatively obvious, have significant difference (P<0.05).
Seminal vesicle index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mice seminal vesicle index obviously reduces, and has significant difference (P<0.01); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, though ribavirin group and comparative example 3 experimental mice seminal vesicle index have rising, but there was no significant difference (P>0.05), all the other medication therapy groups seminal vesicle index elevation amplitude are comparatively obvious, have significant difference (P<0.05).In table 5.
Table 5 on the impact of other organs index (
± S, n=X)
Note: compare with matched group, * p<0.01; Compare with model group, #p<0.05
4 brief summaries
The process of viral passages and virus breeding amplification, because influenza virus is comparatively responsive to the environment in Embryo Gallus domesticus, so viral passages carries out in Embryo Gallus domesticus.And influenza virus can with the erythrocyte generation coagulation of the animal such as people, chicken, principle is the receptor that influenza virus acts on erythrocyte surface, virus is adsorbed on erythrocyte and produces coagulation, has special, responsive and easy and simple to handle advantage, can as of a viruses indentification index.And viral hemoagglutination is tired and can be reflected virus quantity and virulence thereof to a certain extent, utilize influenza virus to the characteristic of chicken red blood cell coagulation, by to the detection of virus after going down to posterity and to understand virus multiplication degree with this be logically rational, the method has special, responsive and easy and simple to handle advantage, can as of a viruses indentification index.
This experimental result shows, and the body temperature difference of model group and matched group has statistical significance, and after the modeling of insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mice, body constitution is weaker, and after virus inoculation, its body temperature keeps lower state always; The body weight of model group mice reduces all gradually, has significant difference with matched group, and wherein after the modeling of insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mice, body constitution is poor, and resistance is more weak, becomes thin gradually and amplitude of variation is larger.Mortality rate is a kind of experimental index being usually used to the protective effect representing host susceptibility and medicine commute host of easy measuring and calculating, from integral level reaction virus virulence.Go out higher death condition after kidney-yang deficiency model mouse inoculation influenza virus, mortality rate is high to 60%, and normal mouse is when inoculating influenza virus, body constitution comparatively kidney-yang deficiency model mice is good, resistance is also relatively strong, only shows anus temperature and declines, be still not enough to cause dead mouse.By the mortality rate of insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model mice be 60% and the temperature decline of diseases caused by exogenous pathogenic factor model mice select the viral allantoic fluid that hemagglutinative titer is 1:320.
The main pathological basis of syndrome of deficiency of kidney-YANG is hypothalamus cells infringement and dysfunction, and the immune system of body, metabolic mechanism also there will be functional and pathologic change simultaneously.Shorten reflection whole body function with mice swimming time in this experiment early-stage Study to reduce, body temperature reduces reflection aversion to cold and cold limbs, and the indexs of correlation such as genitals's index investigate the cold disease of libido, reflect lethargy symptom with autonomic activities number of times.Adopt the method for estradiol modeling comparatively ripe in experiment, most list of references detects the indexs of correlation such as gonadal hormone, model group mice has obvious yang deficiency sign, show as that hair tarnish, tail are cold, asthenia, lethargy etc., comprehensive above index shows to adopt lumbar injection estradiol benzoate to cause Mouse Kidney model of yang asthenia, meets Kidney Theory in TCM yang deficiency disease sign preferably.
Influenza belongs to " influenza " category of the traditional Chinese medical science, influenza infection can cause pulmonary edema, inflammatory exudation, hyperemia, thus cause pulmonary's weight to increase, and the body weight of virus infected mice often reduces or do not increase, thus cause Lung Exponent to raise, Lung Exponent is larger, and pathologic degree is more serious.After FM1 infecting mouse, the anus temperature significance of mice reduces (P<0.01), and mortality rate obviously increases, and Lung Exponent obviously increases.Compared with experiment in vitro, animal experiment in vivo can reflect the effect of body disease-resistant poison from integral level, thus closer to the antiviral state of human body, and the infectious diseases such as influenza more easily attack hypoimmunity crowd, therefore study the medicine with conditioner body immunity function in preventing and controlling influenza process, seem particularly important.
This experiment adopts the low mice of influenza virus collunarium infection immunity, cause Influenza Virus Pneumonia model, with mortality rate, anus temperature, Lung Exponent etc. for evaluation index, after modeling, Lung Exponent obviously raises, and compare research with ribavirin and different pharmaceutical experimental group, thus clear and definite its to the preventive and therapeutic effect of hypoimmunity mice influenza, experimental result show: matched group is without death, the mortality rate of infection model group reaches 60%, illustrates that insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model is reliable; The mortality rate of different pharmaceutical experimental group all comparatively infection model group is low, and after different pharmaceutical experimental group therapeutic intervention is described, mice sign is improved in varying degrees, and can significantly improve the survival rate of model mice.Mouse Weight after influenza virus infection, anus temperature start to decline, rise gradually after different pharmaceutical therapeutic intervention, the perusal lobe of the lung, there is serious viral pneumonia focus in insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group; pathological changes involves more than 2 lobes of the lung; redness, consolidation occur because of inflammatory exudation lung tissue, obviously reduces the Lung Exponent of mice after pharmaceutical intervention, in conjunction with organ index and mortality rate, experimental result illustrates that embodiment 2 experimental group has higher antiviral activity.
two, proportioning optimization Test again
Experimental technique is the same, and positive control drug increases " multi-arch retaining structure group ", and result is as follows:
1.1 impacts on mouse model body weight
Control group mice body weight is in the trend increased gradually; Insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Weight is in the trend continuing to reduce, and 4d body weight is down to minimum, until 6d body weight has not yet to see recovery, compares with control group mice, has significant difference (P<0.01); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Weight, ribavirin group mice 1d body weight reduces, and after pharmaceutical intervention treatment, body weight increases gradually, and 3d plays difference statistical significance (P<0.05); Multi-arch retaining structure group mice, 1st ~ 2d body weight is reduction trend, and 3rd ~ 6d body weight is in the trend increased gradually, and difference has statistical significance (P<0.05); Embodiment 1, embodiment 2 experimental mice 1d weight loss after infection, rise gradually subsequently, 3d plays difference statistical significance (P<0.05); Embodiment 3 experimental mice continued weight is in the trend risen gradually, and 2d rises, and difference has statistics to anticipate (P<0.05).In table 6.
Table 6 affects synopsis to Mouse Weight
1.2 impacts on mouse model body temperature
0th ~ 6d control group mice anus temperature respectively organizes mice apparently higher than other, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mice anus temperature, and always in reduction trend, difference has statistical significance (P<0.01); 3rd ~ 6d insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group body temperature is starkly lower than other drug group, and difference has statistical significance (P<0.05); 3d rises, and ribavirin group, multi-arch retaining structure group and each embodiment group mice anus temperature are gone up in various degree, compare, there was no significant difference (P>0.05) with matched group.In table 7.
Table 7 affects synopsis to mouse temperature
1.3 affect mouse model mortality rate
The impact of influenza infection mouse death rate, matched group occurs without death condition, and insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mortality rate 46.15%, has higher mortality rate.Ribavirin group mortality rate 23.08%, Death prevention rate 50.00%; Multi-arch retaining structure group mortality rate 15.38%, Death prevention rate 66.67%; Embodiment 1 experimental group mortality rate 7.14%, Death prevention rate 83.33%; Wherein embodiment 2,3 experimental group occurs without death condition.In table 8.
Table 8
| Group | N/ only | Dosage/uL | Death prevention rate/% | Death toll/only | Mortality rate/% |
| Matched group | 10 | 50 | \ | 0 | 00 |
| Model group | 13 | 50 | \ | 6 | 46.15 |
| Ribavirin group | 13 | 50 | 50.00 | 3 | 23.08 |
| Multi-arch retaining structure | 13 | 50 | 66.67 | 2 | 15.38 |
| Embodiment 1 experimental group | 14 | 50 | 83.33 | 1 | 7.14 |
| Embodiment 2 experimental group | 14 | 50 | 100 | 0 | 00 |
| Embodiment 3 experimental group | 14 | 50 | 100 | 0 | 00 |
1.4 impacts on mouse model Lung Exponent
Experiment terminates rear model group mouse lung index and the obvious increase of control group mice, difference has statistical significance (P<0.01), after pharmaceutical intervention, each group of mouse lung index compares to have with model group mice and reduces in various degree, difference has statistical significance (P<0.05), shows obviously to improve through treatment pulmonary infection degree.In table 9.
Table 9
Note: compare with matched group, * p<0.05; Compare with model group, #p<0.05
1.5 impacts on mouse model other organs index
Spleen index: compare with control group mice, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse spleen index obviously reduces (P<0.01), each medicine group spleen index there was no significant difference (P>0.05); Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse spleen index, each medication therapy groups mouse spleen index of multi-arch retaining structure group and preferred side's various dose obviously raises (P<0.05), though ribavirin group mouse spleen index has rising to a certain degree, but be not yet increased to normal level, compare with control group mice, difference has statistical significance (P<0.05).
Renal index: compare with control group mice, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Kidney index obviously reduces, (P<0.01), though each medication therapy groups renal index comparatively insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group Mouse Kidney index raises to some extent, but being not yet increased to normal level, and just still there is significant difference (P<0.05) according to organizing Mouse Kidney index.
Thymus index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse thymus index obviously reduces, there is significant difference (P<0.01), each medication therapy groups mouse thymus index has and raises in various degree, compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, have significant difference (P<0.05).Except preferred 2,3 groups, side, though all the other each medication therapy groups mouse thymus indexes have to raise in various degree be not yet increased to normal level.
Testis index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse testis index obviously reduces, there is significant difference (P<0.01), though each medication therapy groups mouse testis index has to raise in various degree still there is significant difference (P<0.05) with Normal group mouse thymus index; Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, though multi-arch retaining structure group mouse testis index has certain amplitude to raise, but there is no significant difference (P>0.05), all the other medication therapy groups mouse testis index elevation amplitude are comparatively obvious, have significant difference (P<0.05).
Seminal vesicle index: compare with matched group, insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group mouse testis index obviously reduces, there is significant difference (P<0.01), raise in various degree though each medication therapy groups mice seminal vesicle index has, still have significant difference (P<0.05) with control group mice; Compare with insufficiency of kidney-YANG diseases caused by exogenous pathogenic factor model group, though each medication therapy groups mice seminal vesicle index has certain amplitude to raise, there is no significant difference (P>0.05).In table 10.
The each medicine group of table 10 on the impact of other organs index (
± S, n=X)
| Group | Spleen index | Thymus index | Renal index | Seminal vesicle index | Testis index |
| Matched group | 0.303±0.068# | 0.230±0.065# | 1.310±0.154# | 0.334±0.071# | 0.490±0.066# |
| Model group | 0.198±0.055* | 0.089±0.041* | 0.989±0.211* | 0.096±0.045* | 0.208±0.076* |
| Ribavirin group | 0.255±0.066 | 0.156±0.035*# | 1.000±0.107* | 0.167±0.049*# | 0.296±0.089*# |
| Multi-arch retaining structure | 0.296±0.064# | 0.180±0.047*# | 1.021±0.083* | 0.167±0.060*# | 0.251±0.045*# |
| Embodiment 1 experimental group | 0.291±0.049# | 0.182±0.043*# | 1.047±0.094* | 0.198±0.027*# | 0.270±0.033*# |
| Embodiment 2 experimental group | 0.302±0.081# | 0.196±0.040# | 1.060±0.176* | 0.205±0.058*# | 0.274±0.073*# |
| Embodiment 3 experimental group | 0.301±0.097# | 0.198±0.044# | 1.057±0.146* | 0.200±0.028*# | 0.286±0.039*# |
Note: compare with matched group, * p<0.01; Compare with model group, #p<0.05.
Claims (4)
1. treat a pharmaceutical composition for influenza, it is characterized in that crude drug weight proportion is as follows:
Herba Ephedrae: Herba Asari: gun additioner=2:3:5;
After being mixed by crude drug, distilled water immersion 30min, adds 8 times respectively and 6 times of water gagings carry out twice decoction, and one decocts 30min, and two decoct 20min, merging filtrate, 3000r/min, and centrifugal 10min makes solid dosage forms or liquid dosage form.
2. treat a pharmaceutical composition for influenza, it is characterized in that crude drug weight proportion is as follows:
Herba Ephedrae: Herba Asari: gun additioner=3:2:7;
After being mixed by crude drug, distilled water immersion 30min, adds 8 times respectively and 6 times of water gagings carry out twice decoction, and one decocts 30min, and two decoct 20min, merging filtrate, 3000r/min, and centrifugal 10min makes solid dosage forms or liquid dosage form.
3. pharmaceutical composition according to claim 1 and 2, is characterized in that solid dosage forms is tablet, capsule, granule or pill.
4. pharmaceutical composition according to claim 1 and 2, is characterized in that liquid dosage form is oral liquid, mixture, Emulsion or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310229899.XA CN103272011B (en) | 2013-06-09 | 2013-06-09 | Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310229899.XA CN103272011B (en) | 2013-06-09 | 2013-06-09 | Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103272011A CN103272011A (en) | 2013-09-04 |
| CN103272011B true CN103272011B (en) | 2015-04-08 |
Family
ID=49054259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310229899.XA Active CN103272011B (en) | 2013-06-09 | 2013-06-09 | Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103272011B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683398A (en) * | 2008-09-27 | 2010-03-31 | 李琪 | Traditional Chinese medicine prescription for treating body continuous external infection chill |
| CN102100755A (en) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | Preparation technology of integrated ephedra, aconite and asarum decoction novel dosage form |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708275B (en) * | 2009-11-27 | 2012-11-28 | 北京市卫生局临床药学研究所 | Chinese medicament for treating flu caused by influenza A(H1N1) and the like |
-
2013
- 2013-06-09 CN CN201310229899.XA patent/CN103272011B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683398A (en) * | 2008-09-27 | 2010-03-31 | 李琪 | Traditional Chinese medicine prescription for treating body continuous external infection chill |
| CN102100755A (en) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | Preparation technology of integrated ephedra, aconite and asarum decoction novel dosage form |
Non-Patent Citations (2)
| Title |
|---|
| 张保国.麻黄附子细辛汤.《伤寒论方剂当代研究》.科学出版社,2011,(第1版),第395、398页,尤其是第395页右栏第5-10行、第398页左栏第16行. * |
| 麻黄细辛附子汤对肾阳虚外感模型小鼠的干预作用;李荣荣等;《中国实验方剂学杂志》;20130228;第19卷(第3期);第226-230页，尤其是第227-228页第2节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103272011A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Anti-influenza virus effects of crude phenylethanoid glycosides isolated from ligustrum purpurascens via inducing endogenous interferon-γ | |
| Shi et al. | Gegen qinlian decoction downregulates the TLR7 signalling pathway to control influenza A virus infection | |
| CN105079226A (en) | Application of traditional Chinese medicine composition to preparation of drug for resisting Middle East respiratory syndrome corona-virus (MERS-CoV) | |
| CN103784538A (en) | Traditional Chinese medicinal compound drug for effectively preventing and treating swine influenza | |
| CN102727687B (en) | Medicine treating chronic fatigue syndrome and its application | |
| CN102423350B (en) | Medicine for treating childhood bronchial asthma and application of medicine | |
| CN103638147A (en) | Traditional Chinese medicine compound for resisting swine influenza virus | |
| CN101569700B (en) | application of Chinese medicinal drug in preparing medicine to treating avian influenza | |
| CN103272011B (en) | Pharmaceutical composition for treating flu and preparation method of pharmaceutical composition | |
| CN105943820A (en) | Traditional Chinese medicine compound for resisting swine influenza and porcine reproductive and respiratory syndrome and extraction method thereof | |
| CN102198192B (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
| CN103845558A (en) | Traditional Chinese medicine used for treating hepatitis | |
| CN103655757A (en) | Traditional Chinese medicine compound for effectively resisting swine influenza virus | |
| CN102908443A (en) | Medicinal composition for therapy or adjuvant therapy of aids, preparation method of medicinal composition and application of medicinal composition | |
| CN103156961B (en) | Medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation | |
| CN106491957B (en) | It is a kind of for treating the preparation method of the Chinese medicine composition of bronchial asthma | |
| Siddiqui | COVID-19 novel corona virus control and preventions in china and discussing their national success to back to normal life, while world is combatting the deadly viral pandemic | |
| CN103652192A (en) | Liver protection tea | |
| CN103652199A (en) | Liver-protecting schisandra chinensis tea | |
| CN104721388B (en) | The Chinese medicine composition and its preparation method and application for treating people at highest risk's influenza severe | |
| CN105982961A (en) | Traditional Chinese medicine composition with functions of resisting HIV infection and HBV infection and preparation method and application thereof | |
| CN104825741A (en) | Traditional Chinese medicine compound for preventing and treating influenza and preparation thereof | |
| CN106421329A (en) | Traditional Chinese medicine compound prescription for simultaneously resisting swine infuenza and porcine reproductive and respiratory syndrome and extraction method thereof | |
| CN115737712A (en) | Traditional Chinese medicine composition for treating children influenza heat-toxin attacking lung syndrome and preparation method of granules | |
| Du et al. | Experimental study on acute toxicity of Lucao Wenban granules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |